Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Assembly Biosciences (NQ: ASMB )

16.56 -0.42 (-2.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Assembly Biosciences

< Previous 1 2 Next >
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – 
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces $12.6 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces Effective Date of Reverse Stock Split
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Provides Anticipated Development Milestones for 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
From Assembly Biosciences, Inc.
Via GlobeNewswire
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
From Assembly Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.